Seattle Genetics seeking a test to ID who will respond to Adcetris

Seattle Genetics, maker of the antibody drug conjugate Adcetris for relapsed or refractory Hodgkin's lymphoma and for anaplastic large cell lymphoma, is announcing a collaboration with Ventana Medical Systems, Inc., a member of the Roche Group.

The importance of this collaboration agreement is that Ventana will be attempting to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on the expression of the protein CD30 on the surface of cancerous cells.

As part of the ongoing clinical development of Adcetris, Seattle Genetics is in the midst of organizing and initiating a pair of Phase III clinical trials that will employ this companion diagnostic:

-- One trial will explore the diagnostic in CD30-positive cutaneous T-cell lymphoma (CTCL) patients
-- The other trial will explore the diagnostic in CD30-positive mature T-cell lymphoma (MTCL) patients.

“Availability of a CD30 companion diagnostic will bring us a step closer to our vision of a more personalized, target-based approach to the treatment of cancer, and supports our broad ongoing and planned clinical development of Adcetris for CD30-positive patients in need,” said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics.

Source: MarketWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap